Please activate JavaScript!
Please install Adobe Flash Player, click here for download

kontinenz aktuell - Ausgabe 02-2015

kontinenz aktuell Juli/2015 19 Rerence List (1) Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T et al. Randomized dou- ble-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a be- ta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013 February; 63(2): 296–305 (2) Bauer RM, Gratzke C, Roosen A, Hocaoglu Y, Mayer ME, Buchner A et al. Patient-reported side ef- fects of intradetrusor botulinum toxin type a for idio- pathic overactive bladder syndrome. Urol Int 2011 February; 86(1): 68–72 (3) Goldman HB, Wyndaele JJ, Kaplan SA, Wang JT, Ntanios F. Defining response and non-response to treatment in patients with overactive bladder: a systematic review. Curr Med Res Opin 2014 March; 30(3): 509–26 (4) Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S. Correlation between improvements in Over- active Bladder Symptom Score and health-related quali- ty of life questionnaires in overactive bladder patients treated with an antimuscarinic drug. Neurourol Urodyn 2011 September; 30(7): 1309–14 (5) Jundt K, Schreyer K, Friese K, Peschers U. Anti- cholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet 2011 Septem- ber;284(3): 663–6 (6) Wagg A, Compion G, Fahey A, Siddiqui E. Per- sistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012 December; 110(11): 1767–74 (7) Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM. The management of overactive bladder syndrome. BMJ 2012; 344: e2365 (8) Lee HE, Cho SY, Lee S, Kim M, Oh SJ. Short-term Effects of a Systematized Bladder Training Program for Idiopathic Overactive Bladder: A Prospective Study. Int Neurourol J 2013 March;17(1):11–7 (9) Townsend MK, Resnick NM, Grodstein F. Caffei- ne intake and risk of urinary incontinence progressi- on among women. Obstet Gynecol 2012 May;119(5): 950–7 (10) Jura YH, Townsend MK, Curhan GC, Resnick NM, Grodstein F. Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J Urol 2011 May;185(5):1775–80 (11) Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM et al. Weight loss to treat urinary in- continence in overweight and obese women. N Engl J Med 2009 January 29; 360(5): 481–90 (12) Ouslander JG, Uman GC, Urman HN, Ruben- stein LZ. Incontinence among nursing home pa- tients: clinical and functional correlates. J Am Ger- iatr Soc 1987 April; 35(4): 324–30 (13) Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibi- tors in type 2 diabetes: a meta-analysis of randomi- zed clinical trials. Diabetes Obes Metab 2014 May; 16(5): 457–66 (14) Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement Geriatr Cogn Disord 2013; 35(5–6): 239–48 (15) Kemmer H, Mathes AM, Dilk O, Groschel A, Grass C, Stockle M. Obstructive sleep apnea syn- drome is associated with overactive bladder and ur- gency incontinence in men. Sleep 2009 February; 32(2): 271–5 (16) Schwantes U, Grosse J, Wiedemann A. Re- fractory overactive bladder: a common problem? Int Urogynecol J 2015 March 20 (17) Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivi- ty. Urology 2003 November; 62(5 Suppl 2): 28–37 (18) Hessdoerfer E, Jundt K, Peschers U. Is a dip- stick test sufficient to exclude urinary tract infection in women with overactive bladder? Int Urogynecol J 2011 February; 22(2): 229–32 (19) Lee YS, Kim JY, Kim JC, Park WH, Choo MS, Lee KS. Prevalence and treatment efficacy of geni- tourinary mycoplasmas in women with overactive bladder symptoms. Korean J Urol 2010 September; 51(9): 625–30 (20) Digesu GA, Sadeghi P, Sharma S, Puccini F, Tu- baro A, Fernando R et al. The importance of cystos- copy and bladder biopsy in women with refractory overactive bladder: the urogynaecologist’s point of view? Eur J Obstet Gynecol Reprod Biol 2013 July; 169(2): 408–11 (21) Kociszewski J, Fabian G, Grothey S, Viereck V, Fusgen I, Wiedemann A. [Tethered tape or the fourth factor. A new cause of recurrent stress incontinence after midurethral tape procedures vaginal tape inser- tion]. Urologe A 2014 January; 53(1): 55–61 (22) Kociszewski J, Rautenberg O, Kolben S, Eber- hard J, Hilgers R, Viereck V. Tape functionality: posi- tion, change in shape, and outcome after TVT pro- cedure--mid-term results. Int Urogynecol J 2010 July; 21(7): 795–800 (23) Ku JH, Ko DW, Cho JY, Oh SJ. Correlation bet- ween prostatic urethral angle and bladder outlet ob- struction index in patients with lower urinary tract symptoms. Urology 2010 June; 75(6): 1467–71 (24) Malhotra B, Darsey E, Crownover P, Fang J, Glue P. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cyto- chrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol 2011 August; 72(2): 226–34 (25) Oishi M, Chiba K, Malhotra B, Suwa T. Effect of the CYP2D6*10 genotype on tolterodine phar- macokinetics. Drug Metab Dispos 2010 September; 38(9): 1456–63 (26) Hinata N, Shirakawa T, Okada H, Achaya B, Kamidono S, Gotoh A. Quantitative analysis of the levels of expression of muscarinic receptor subtype RNA in the detrusor muscle of patients with overacti- ve bladder. Mol Diagn 2004; 8(1): 17–22 (27) Pontari MA, Braverman AS, Ruggieri MR, Sr. The M2 muscarinic receptor mediates in vitro blad- der contractions from patients with neurogenic blad- der dysfunction. Am J Physiol Regul Integr Comp Physiol 2004 May; 286(5): R874–R880 (28) Braverman AS, Ruggieri MR, Sr. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am J Phy- siol Regul Integr Comp Physiol 2003 September; 285(3): R701–R708 (29) Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005 April; 144(8): 1089–99 (30) Nelson CP, Gupta P, Napier CM, Nahorski SR, Challiss RA. Functional selectivity of muscarinic recep- tor antagonists for inhibition of M3-mediated phos- phoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther 2004 September; 310(3): 1255–65 (31) Ikeda K, Kobayashi S, Suzuki M, Miyata K, Ta- keuchi M, Yamada T et al. M(3) receptor antago- nism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002 August; 366(2): 97–103 (32) Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert KD. Effective treatment of neu- rogenic detrusor dysfunction by combined high-do- sed antimuscarinics without increased side-effects. Eur Urol 2008 May; 53(5): 1021–8 (33) Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doub- ling the recommended antimuscarinic dosage. Neu- rourol Urodyn 2006; 25(5): 441–5 (34) Bolduc S, Moore K, Lebel S, Lamontagne P, Ha- mel M. Double anticholinergic therapy for refractory overactive bladder. J Urol 2009 October; 182(4 Suppl): 2033–8 (35) Nardulli R, Losavio E, Ranieri M, Fiore P, Meg- na G, Bellomo RG et al. Combined antimuscarinics for treatment of neurogenic overactive bladder. Int J Immunopathol Pharmacol 2012 January; 25(1 Suppl): 35S–41S (36) Nadeau G, Schroder A, Moore K, Genois L, Lamontagne P, Hamel M et al. Double anticholiner- gic therapy for refractory neurogenic and nonneuro- genic detrusor overactivity in children: Long-term re- sults of a prospective open-label study. Can Urol As- soc J 2014 May; 8(5–6): 175–80 (37) Kosilov KV, Loparev SA, Ivanovskaya MA, Ko- silova LV. Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Ther Adv Urol 2014 December; 6(6): 215–23 (38) Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R et al. Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). Eur Urol 2014 Febru- ary 19 (39) Kurita N, Yamazaki S, Fukumori N, Otoshi K, Otani K, Sekiguchi M et al. Overactive bladder symptom severity is associated with falls in commu- nity-dwelling adults: LOHAS study. BMJ Open 2013; 3(5) (40) Moon SJ, Kim YT, Lee TY, Moon H, Kim MJ, Kim SA et al. The influence of an overactive bladder on falling: a study of females aged 40 and older in the community. Int Neurourol J 2011 March; 15 (1): 41–7 (41) Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract 2010 August; 64 (9): 1279–86 (42) Wiedemann A and Schwantes PA. Antimusca- rinic drugs for the treatment of overactive bladder: are they really all the same? – A comparative re- view of data pertaining to pharmacological and physiological aspects. 2007. Report No.: Eur J Ger- iatrics 9 (2007) (43) Wagg A, Khullar V, Michel MC, Oelke M, Da- rekar A, Bitoun CE. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extensi- on of the SOFIA trial. Neurourol Urodyn 2014 Ja- nuary; 33(1): 106–14 (44) Dubeau CE, Kraus SR, Griebling TL, Newman DK, Wyman JF, Johnson TM et al. Effect of fesoterodi- ne in vulnerable elderly subjects with urgency inconti- nence: a double-blind, placebo controlled trial. J Urol 2014 February; 191 (2): 395–404 (45) Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013 July; 64 (1): 74–81 (46) Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S et al. A comprehensive non-clinical evaluation of the CNS penetration po- tential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011 Au- gust; 72(2): 235–46 Übersichtsarbeit kontinenz aktuell Juli/201519